HES V2.0——肝细胞癌早筛的新希望
近期发表在《Hepatology》上的一项重要的Ⅲ期生物标志物研究展现了HES V2.0的优越性，该检测方法在早期HCC的识别上表现远超当前广泛使用的GALAD评分系统。该研究收集了2016年12月至2022年2月期间在德克萨斯州各大肝病诊所接受肝硬化监测的患者样本，经过长达六个月的跟踪与评估，共分析了2331名肝硬化患者的数据，其中125名患者在随访期间被确诊为肝细胞癌。
Mets name Opening Day starter: ‘He’s worked really hard'
PORT ST. LUCIE, Fla. — Clay Holmes — a former Yankees closer — was named the Opening Day starter for the Mets on Friday. “He ...
Scaffolding set to remain on Dumfries and Galloway landmark nearly six years after being put up
MacLellan’s Castle in Kirkcudbright is one of a number of HES sites across Dumfries and Galloway where public access is ...